KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
11.90
-0.29 (-2.42%)
At close: May 9, 2025, 4:00 PM
12.49
+0.60 (5.00%)
After-hours: May 9, 2025, 5:39 PM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 150 employees as of April 30, 2024. The number of employees increased by 32 or 27.12% compared to the previous year.
Employees
150
Change (1Y)
32
Growth (1Y)
27.12%
Revenue / Employee
n/a
Profits / Employee
-$1,172,447
Market Cap
591.62M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
KALV News
- 9 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference - Business Wire
- 4 weeks ago - KalVista: Poised For Rare Disease Transformation - Seeking Alpha
- 4 weeks ago - KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Business Wire
- 2 months ago - KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
- 2 months ago - KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - Business Wire